Supernus Pharmaceuticals (SUPN) Tops Q3 EPS by 6c

Supernus Pharmaceuticals (NASDAQ: SUPN) reported Q3 EPS of $0.08, $0.06 better than the analyst estimate of $0.02. Revenue for the quarter came in at $38.6 million versus the consensus estimate of $38.1 million.

For earnings history and earnings-related data on Supernus Pharmaceuticals (SUPN) click here.

You May Also Be Interested In

• EU proposes to curb Airbnb and short-term rentals amid housing shortage
• Goldman Sachs Downgrades Schindler Holding AG (SCHN:SW) (SHLAF) to Sell
• ICICI Bank (ICICIBC:IN) (IBN) PT Raised to INR2,000 at Goldman Sachs